Patient and treatment characteristics
| Characteristic | Value (%) |
| No of patients | 182 |
| Age (years) | |
| Median | 67 |
| Range | 40.8–87.9 |
| Race | |
| Asian | 1 (0.5) |
| Black or African American | 2 (1.1) |
| Hispanic/Latino | 0 (0.0) |
| White | 173 (95.1) |
| Other or decline to answer | 6 (3.3) |
| Histology | |
| Papillary serous | 114 (62.6) |
| Clear cell | 35 (19.2) |
| Mixed | 33 (18.1) |
| FIGO 2009 stage | |
| IA | 160 (87.9) |
| No invasion* | 54 (29.7) |
| <50% invasion | 106 (58.2) |
| IB | 22 (12.1) |
| Total abdominal hysterectomy/Bilateral salpingo-opherectomy | |
| Without lymph node evaluation | 9 (4.9) |
| Sentinel lymph node | 50 (27.5) |
| Full lymph node dissection | 123 (67.6) |
| Omentum explored | |
| Yes | 141 (77.5) |
| No | 41 (22.5) |
| Cytology obtained | |
| Yes | 160 (87.9) |
| No | 22 (12.1) |
| Surgery to implant (weeks) | |
| Median | 6.4 |
| IQR | 5.0–7.7 |
| Vaginal brachytherapy (dose/fractionation) | |
| 14 gray/2 fractions | 1 (0.5) |
| 21 gray/3 fractions | 181 (99.5) |
| Chemotherapy | |
| Yes | 76 (41.8) |
| No | 106 (58.2) |
| No of patients | 76 |
| Chemotherapy timing | |
| Prior to brachytherapy | 7 (9.2) |
| After brachytherapy | 69 (90.8) |
| Chemotherapy | |
| Carboplatin/paclitaxel | 74 (97.4) |
| Other | 2 (2.6) |
| Chemotherapy cycles | |
| 1–3 | 17 (22.3) |
| 4–6 | 59 (77.6) |
*10 patients had no residual disease on final pathology.
FIGO, International Federation of Gynecology and Obstetrics.